|
schizophrenia |
86 |
|
covid-19 |
53 |
|
first-episode psychosis |
47 |
|
psychosis |
44 |
|
negative symptoms |
38 |
|
psychotic disorders |
37 |
|
youth mental health |
36 |
|
depression |
35 |
|
mental health |
32 |
|
early psychosis |
29 |
|
stigma |
29 |
|
predictors |
28 |
|
risk factors |
28 |
|
functioning |
27 |
|
relapse |
25 |
|
first episode |
24 |
|
medical sciences |
24 |
|
psychiatry and neurology |
24 |
|
first-episode schizophrenia |
23 |
|
duration of untreated psychosis |
22 |
|
early intervention |
22 |
|
humans |
22 |
|
remission |
22 |
|
cognitive impairment |
21 |
|
epidemiology |
21 |
|
hong kong |
21 |
|
rumination |
21 |
|
social unrest |
21 |
|
cognition |
20 |
|
physical activity |
20 |
|
anxiety |
19 |
|
insight |
19 |
|
adolescent |
18 |
|
antipsychotics |
18 |
|
executive function |
18 |
|
female |
18 |
|
assessment |
17 |
|
psychiatric status rating scales |
17 |
|
psychopathology |
17 |
|
stress |
17 |
|
child psychosocial problems |
16 |
|
coronavirus |
16 |
|
delusional disorder |
16 |
|
depressive symptoms |
16 |
|
functional outcome |
16 |
|
healthcare workers |
16 |
|
home confinement |
16 |
|
hospital policies |
16 |
|
male |
16 |
|
perceived stress |
16 |
|
post-traumatic stress disorder |
16 |
|
prevalence |
16 |
|
psychological wellbeing |
16 |
|
schizophrenic psychology |
16 |
|
school closure |
16 |
|
adolescents |
15 |
|
age of onset |
15 |
|
amotivation |
15 |
|
cost-effectiveness |
15 |
|
dopamine |
15 |
|
employment |
15 |
|
first-episode |
15 |
|
quality of life |
15 |
|
adult |
14 |
|
avolition |
14 |
|
medication adherence |
14 |
|
randomized controlled trial |
14 |
|
recovery |
14 |
|
caregivers |
13 |
|
chinese |
13 |
|
early diagnosis |
13 |
|
mental health services |
13 |
|
outcome |
13 |
|
premorbid adjustment |
13 |
|
psychotic disorders - diagnosis |
13 |
|
symptomatology |
13 |
|
validation study |
13 |
|
adherence |
12 |
|
evaluation |
12 |
|
experience sampling method |
12 |
|
momentary positive affect |
12 |
|
recurrence |
12 |
|
diminished expression |
11 |
|
long-term outcomes |
11 |
|
longitudinal |
11 |
|
longitudinal follow-up |
11 |
|
maintenance treatment |
11 |
|
pandemic |
11 |
|
pattern glare |
11 |
|
perceptual distortions |
11 |
|
processing speed |
11 |
|
prospective follow-up |
11 |
|
self-reference |
11 |
|
young people |
11 |
|
youth |
11 |
|
antipsychotic |
10 |
|
antipsychotic agents - therapeutic use |
10 |
|
cognitive function |
10 |
|
cognitive functions |
10 |
|
community-based intervention |
10 |
|
disengagement |
10 |
|
double blind |
10 |
|
f-dopa |
10 |
|
maintenance |
10 |
|
mindfulness |
10 |
|
positron emission tomography |
10 |
|
relapse prevention |
10 |
|
sex difference |
10 |
|
stereotyping |
10 |
|
striatal dopamine capacity synthesis |
10 |
|
treatment adherence |
10 |
|
youth-friendly |
10 |
|
affect |
9 |
|
attitude |
9 |
|
delusions |
9 |
|
early medical intervention - methods - trends |
9 |
|
epidemiological youth |
9 |
|
esm |
9 |
|
exercise |
9 |
|
hallucination |
9 |
|
health education - methods |
9 |
|
ideas of reference |
9 |
|
internalized stigma |
9 |
|
intervention |
9 |
|
life events |
9 |
|
loneliness |
9 |
|
memory |
9 |
|
mental health services - trends |
9 |
|
momentary assessment |
9 |
|
motivational deficits |
9 |
|
neuropsychological tests |
9 |
|
omicron |
9 |
|
program development |
9 |
|
psychotic disorders - therapy |
9 |
|
psychotic symptoms |
9 |
|
psychotic-like experiences |
9 |
|
public stigma |
9 |
|
smartphone overuse |
9 |
|
social context |
9 |
|
time factors |
9 |
|
traumatic events |
9 |
|
treatment outcome |
9 |
|
brain - ultrastructure |
8 |
|
cluster analysis |
8 |
|
cognition disorders - etiology |
8 |
|
community |
8 |
|
corpus striatum |
8 |
|
delusions - diagnosis |
8 |
|
delusions - etiology |
8 |
|
diffusion tensor imaging |
8 |
|
discontinuation |
8 |
|
dose-dependent effect |
8 |
|
drug-naive |
8 |
|
eye-gaze perception |
8 |
|
follow-up studies |
8 |
|
fractional anisotropy |
8 |
|
growth mixture modeling |
8 |
|
interview, psychological - methods |
8 |
|
latent class analysis |
8 |
|
long-term outcome |
8 |
|
mass screening |
8 |
|
mass screening - methods |
8 |
|
media |
8 |
|
mentalization |
8 |
|
meta-analysis |
8 |
|
mode of onset |
8 |
|
mortality |
8 |
|
mri |
8 |
|
panss |
8 |
|
persistent psychotic experience |
8 |
|
prediction |
8 |
|
prospective study |
8 |
|
psychotic disorder |
8 |
|
psychotic disorders - complications |
8 |
|
ptsd symptoms |
8 |
|
raclopride |
8 |
|
remission induction |
8 |
|
resilience |
8 |
|
review |
8 |
|
schizophrenia - complications |
8 |
|
schizophrenia - diagnosis |
8 |
|
schizophrenia - pathology |
8 |
|
self-discrepancy |
8 |
|
self-stigma |
8 |
|
semantic |
8 |
|
suicide |
8 |
|
temporal lobe - ultrastructure |
8 |
|
trauma exposure |
8 |
|
age factors |
7 |
|
amino acid substitution - genetics |
7 |
|
anti-stigma campaigns |
7 |
|
antipsychotic agents - administration and dosage |
7 |
|
asian continental ancestry group - genetics |
7 |
|
behavioral symptoms - etiology - psychology - therapy |
7 |
|
big five |
7 |
|
caudate |
7 |
|
clozapine |
7 |
|
cognitive structure |
7 |
|
content-dependent process |
7 |
|
course |
7 |
|
duration of untreated psychosis (dup) |
7 |
|
effort-cost computation |
7 |
|
endophenotype |
7 |
|
executive function - physiology |
7 |
|
extended early intervention |
7 |
|
first episode psychosis |
7 |
|
first-episode schizophrenia spectrum disorder |
7 |
|
functional remission |
7 |
|
gender |
7 |
|
genotype |
7 |
|
health service accessibility |
7 |
|
help-seeking |
7 |
|
help‐seeking |
7 |
|
hospitalization |
7 |
|
illness disclosure |
7 |
|
late-onset psychosis |
7 |
|
latent class growth analysis |
7 |
|
long-term follow-up |
7 |
|
longitudinal course |
7 |
|
maternal age |
7 |
|
medication-naïve |
7 |
|
mental health literacy |
7 |
|
mental health services - organization and administration |
7 |
|
motivational impairment |
7 |
|
mutations |
7 |
|
network analysis |
7 |
|
neuregulin 1 |
7 |
|
neuregulin-1 - genetics |
7 |
|
neurobiology |
7 |
|
neuropsychology |
7 |
|
nomenclature |
7 |
|
overcontrolled |
7 |
|
paternal age |
7 |
|
pathways |
7 |
|
persistent primary negative symptoms |
7 |
|
personality |
7 |
|
polymorphism, single nucleotide - genetics |
7 |
|
predictive value of tests |
7 |
|
prodrome |
7 |
|
prognosis |
7 |
|
psychoeducation |
7 |
|
psychosocial |
7 |
|
psychotherapy - methods |
7 |
|
psychotic disorders - diagnosis - drug therapy - therapy |
7 |
|
psychotic disorders - diagnosis - psychology |
7 |
|
psychotic disorders - drug therapy |
7 |
|
ptsd symptoms, women mental health |
7 |
|
questionnaires |
7 |
|
real-world functioning |
7 |
|
rehospitalization |
7 |
|
resilient |
7 |
|
risk taking |
7 |
|
schizophrenia - complications - diagnosis - epidemiology - therapy |
7 |
|
schizophrenia - genetics |
7 |
|
sex characteristics |
7 |
|
sex factors |
7 |
|
six elements |
7 |
|
sociodemographic correlates |
7 |
|
stability |
7 |
|
stigmatization |
7 |
|
stressful life event |
7 |
|
suicide attempt |
7 |
|
suicide, attempted - psychology |
7 |
|
terminology as topic |
7 |
|
treatment delay |
7 |
|
undercontrolled |
7 |
|
unemployment |
7 |
|
v266l |
7 |
|
violence |
7 |
|
adults |
6 |
|
affective psychoses |
6 |
|
anti-psychotics |
6 |
|
antipsychotic agents - pharmacology - therapeutic use |
6 |
|
anxiety disorders |
6 |
|
app |
6 |
|
arhgap4 |
6 |
|
asia |
6 |
|
asian continental ancestry group |
6 |
|
at‐risk mental state |
6 |
|
balloon analogue risk task |
6 |
|
blinking |
6 |
|
brain |
6 |
|
brain - drug effects - metabolism - pathology |
6 |
|
categorization |
6 |
|
category fluency |
6 |
|
china |
6 |
|
chinese zodiac signs |
6 |
|
chizophrenia |
6 |
|
clinical high‐risk |
6 |
|
clinical predictors |
6 |
|
clozapine-resistant schizophrenia |
6 |
|
cognitive clusters |
6 |
|
cognitive flexibility |
6 |
|
cognitive heterogeneity |
6 |
|
cognitive insights |
6 |
|
communityolder |
6 |
|
compliance |
6 |
|
concepts |
6 |
|
cultural sensitivity |
6 |
|
culture |
6 |
|
delivery of health care - standards |
6 |
|
dementia |
6 |
|
depressive mood |
6 |
|
development |
6 |
|
dibenzothiazepines - therapeutic use |
6 |
|
digit symbol test |
6 |
|
digital technologies |
6 |
|
double-blind method |
6 |
|
drug naïve |
6 |
|
early intervention service |
6 |
|
early medical intervention - standards |
6 |
|
effort allocation |
6 |
|
effort discounting |
6 |
|
effort-based decision-making |
6 |
|
ethnic minority |
6 |
|
fitmind |
6 |
|
fractionation |
6 |
|
genetics |
6 |
|
genome-wide association study |
6 |
|
global functioning |
6 |
|
guideline |
6 |
|
han chinese |
6 |
|
health surveys |
6 |
|
history |
6 |
|
human |
6 |
|
illness attributional belief |
6 |
|
immersive |
6 |
|
incidence |
6 |
|
internal feed-forward |
6 |
|
interview, psychological |
6 |
|
knowledge |
6 |
|
labelling |
6 |
|
letter |
6 |
|
lifetime prevalence |
6 |
|
long-term trajectories |
6 |
|
longitudinal negative symptoms |
6 |
|
magnetic resonance imaging |
6 |
|
mecp2 |
6 |
|
mental disorders / epidemiology |
6 |
|
mental health services - standards |
6 |
|
meta analysis |
6 |
|
mhealth |
6 |
|
mindfulness-based intervention |
6 |
|
naturalistic |
6 |
|
negative treatment attitude |
6 |
|
neurocognition |
6 |
|
neuroleptic agent |
6 |
|
neuronal plasticity - drug effects |
6 |
|
outcomes |
6 |
|
paranoid schizophrenia |
6 |
|
passivity experiences |
6 |
|
path analysis |
6 |
|
pilot |
6 |
|
pilot trial |
6 |
|
polypharmacy |
6 |
|
population surveys |
6 |
|
predictive validity |
6 |
|
primary negative symptoms |
6 |
|
priority journal |
6 |
|
psychiatric comorbidity |
6 |
|
psychological symptoms |
6 |
|
psychosocial functioning |
6 |
|
recommendation |
6 |
|
reliability |
6 |
|
renbp |
6 |
|
risk aversion |
6 |
|
risky–gains task |
6 |
|
schizophrenia - drug therapy - physiopathology |
6 |
|
schizophrenia-spectrum disorder |
6 |
|
selective attention |
6 |
|
self-monitoring |
6 |
|
smartphone |
6 |
|
social functioning |
6 |
|
subjective quality of life |
6 |
|
suicide-statistics-and-numerical-data |
6 |
|
switching |
6 |
|
symptomatic remission |
6 |
|
systematic review |
6 |
|
treatment |
6 |
|
treatment resistant schizophrenia |
6 |
|
treatment-resistant schizophrenia |
6 |
|
ultra-high risk |
6 |
|
validation |
6 |
|
virtual reality |
6 |
|
vocational outcome |
6 |
|
voxel-based morphometry |
6 |
|
vr |
6 |
|
web-based |
6 |
|
yoga |
6 |
|
10-year follow-up |
5 |
|
10-year outcomes |
5 |
|
1st episode |
5 |
|
adolescent onset |
5 |
|
adult onset |
5 |
|
affiliate stigma |
5 |
|
aggressive behavior |
5 |
|
alogia |
5 |
|
anhedonia |
5 |
|
asian network for early psychosis |
5 |
|
asociality |
5 |
|
at-risk mental state |
5 |
|
auditory cortex |
5 |
|
auditory hallucination |
5 |
|
behavior |
5 |
|
blunted affect |
5 |
|
brain size |
5 |
|
caregiver |
5 |
|
caregivers’ distress |
5 |
|
case management |
5 |
|
chinese population |
5 |
|
chronic schizophrenia |
5 |
|
clinical high-risk |
5 |
|
cognition disorders - psychology |
5 |
|
community mental health service |
5 |
|
community mental health services |
5 |
|
community mental health services - organization and administration - utilization |
5 |
|
contact |
5 |
|
cortical thickness (brain) |
5 |
|
dangerous |
5 |
|
diagnostic specificity |
5 |
|
discrimination |
5 |
|
disease severity |
5 |
|
drug knowledge |
5 |
|
early detection |
5 |
|
early medical intervention |
5 |
|
express emotion |
5 |
|
face concern |
5 |
|
family caregiver |
5 |
|
females |
5 |
|
financial deprivation |
5 |
|
first psychosis |
5 |
|
first-episode mania |
5 |
|
firstepisode psychosis |
5 |
|
first‐episode psychosis |
5 |
|
follow-up study |
5 |
|
formal thought disorder |
5 |
|
gad-7 |
5 |
|
gender differences |
5 |
|
gender effect |
5 |
|
general self-efficacy |
5 |
|
genetic high-risk |
5 |
|
glucose supplement |
5 |
|
health-care professionals' attitude |
5 |
|
hong kong - epidemiology |
5 |
|
hopelessness |
5 |
|
knowledge about psychosis |
5 |
|
knowledge of medication |
5 |
|
language |
5 |
|
language disorganization |
5 |
|
learned irrelevance |
5 |
|
media report violent |
5 |
|
mediators |
5 |
|
medication |
5 |
|
medication discontinuation |
5 |
|
medication knowledge |
5 |
|
meta-aggregation |
5 |
|
metabolic screening |
5 |
|
metabolic syndrome |
5 |
|
neurocognitive impairment |
5 |
|
neurological examination abnormalities |
5 |
|
newspapers |
5 |
|
patient demographics |
5 |
|
perceived public stigma |
5 |
|
physical exercise |
5 |
|
positive symptoms |
5 |
|
predictive factors |
5 |
|
program |
5 |
|
programme evaluation |
5 |
|
psychiatric emergency admission |
5 |
|
psychiatry |
5 |
|
psychotic disorders - diagnosis - drug therapy - psychology |
5 |
|
psychotic-like experience |
5 |
|
public awareness |
5 |
|
qualitative |
5 |
|
qualitative systematic review |
5 |
|
rasch model |
5 |
|
relapse risk perception |
5 |
|
salivary cortisol |
5 |
|
schizophrenia, first-episode |
5 |
|
schizophrenia-spectrum disorders |
5 |
|
school-based programme |
5 |
|
seasonality |
5 |
|
severity of illness index |
5 |
|
sex differences |
5 |
|
social contact |
5 |
|
social stigma |
5 |
|
stigma of mental illness |
5 |
|
stigma reduction |
5 |
|
striato-thalamic volume |
5 |
|
suicidal behavior |
5 |
|
suicidal ideation |
5 |
|
suicide - statistics & numerical data |
5 |
|
syntax |
5 |
|
tai-chi |
5 |
|
trait |
5 |
|
trial |
5 |
|
validity |
5 |
|
video |
5 |
|
working memory |
5 |
|
youth and adult |
5 |
|
youth psychosis |
5 |
|
acute coronary syndrome |
4 |
|
aged |
4 |
|
attribution questionnaire |
4 |
|
bipolar disorder |
4 |
|
cardioprotective medications |
4 |
|
case-control studies |
4 |
|
celebrity death |
4 |
|
chinese context |
4 |
|
family - psychology |
4 |
|
flow model of rumination |
4 |
|
gene-environment interaction |
4 |
|
health service utilization |
4 |
|
hippocampus |
4 |
|
hong kong sar |
4 |
|
imitation |
4 |
|
latent structure |
4 |
|
mental disorders |
4 |
|
mental disorders - complications - diagnosis - epidemiology |
4 |
|
mental illness |
4 |
|
population surveillance - methods |
4 |
|
psychotherapy |
4 |
|
randomized controlled trial (rct) |
4 |
|
revascularization |
4 |
|
salience |
4 |
|
schizophrenia - drug therapy |
4 |
|
suicide - psychology - statistics & numerical data |
4 |
|
suicide, attempted - psychology - statistics & numerical data |
4 |
|
technological advances |
4 |
|
treatment inequality |
4 |
|
treatment response |
4 |
|
adaptation, psychological |
3 |
|
aerobic exercise |
3 |
|
affective disorders |
3 |
|
art therapy |
3 |
|
attention |
3 |
|
attitude to health |
3 |
|
bart 2 |
3 |
|
cbt |
3 |
|
china - epidemiology |
3 |
|
citizenship |
3 |
|
cognitive behavioural therapy |
3 |
|
communication |
3 |
|
community arts |
3 |
|
complication burden |
3 |
|
context-memory |
3 |
|
cortisol |
3 |
|
criminal behavior |
3 |
|
cspg5 |
3 |
|
cultural characteristics |
3 |
|
cultural differences |
3 |
|
decision making |
3 |
|
diabetes |
3 |
|
diabetes complications |
3 |
|
diabetes mellitus |
3 |
|
distortions |
3 |
|
diurnal slope |
3 |
|
empathy |
3 |
|
erbb4 |
3 |
|
excess life-years lost |
3 |
|
family |
3 |
|
family therapy |
3 |
|
forensic psychiatry |
3 |
|
genetic association |
3 |
|
group psychotherapy |
3 |
|
hayling |
3 |
|
homelessness |
3 |
|
housing |
3 |
|
interaction |
3 |
|
ischemic stroke |
3 |
|
lateral ventricles |
3 |
|
life expectancy |
3 |
|
life years lost |
3 |
|
living environment |
3 |
|
logistic models |
3 |
|
long term |
3 |
|
mental disorders - epidemiology |
3 |
|
middle aged |
3 |
|
mind-body intervention |
3 |
|
mortality gap |
3 |
|
mortality trend |
3 |
|
mortalityschizophrenia |
3 |
|
multivariate analysis |
3 |
|
needs assessment |
3 |
|
neighbourhood |
3 |
|
neuregulin-1 |
3 |
|
neurological soft signs |
3 |
|
non-affective psychoses |
3 |
|
optimism |
3 |
|
outcome assessment (health care) |
3 |
|
patients - psychology |
3 |
|
physician-patient relations |
3 |
|
population-based |
3 |
|
population-based study |
3 |
|
prejudice |
3 |
|
premature mortality |
3 |
|
prose memory |
3 |
|
psychological adaptation |
3 |
|
psychological autopsy |
3 |
|
psychological distress |
3 |
|
psychosocial intervention |
3 |
|
psychotic disorders - rehabilitation |
3 |
|
risk factor |
3 |
|
risky decision-making |
3 |
|
rural area |
3 |
|
schools |
3 |
|
social change |
3 |
|
social support |
3 |
|
stroke |
3 |
|
structural neuroimaging |
3 |
|
students - statistics & numerical data |
3 |
|
suicide, attempted - statistics & numerical data |
3 |
|
tai chi |
3 |
|
temporal cortex |
3 |
|
unemployment - psychology - statistics & numerical data |
3 |
|
verbal memory |
3 |
|
years of potential life lost |
3 |
|
"endophenotypes" |
2 |
|
age distribution |
2 |
|
attitudes |
2 |
|
australia |
2 |
|
awareness |
2 |
|
basal ganglia |
2 |
|
candidate gene |
2 |
|
caregivers - psychology |
2 |
|
carer |
2 |
|
case-control |
2 |
|
cerebral |
2 |
|
cerebral ventricles - abnormalities |
2 |
|
chinese caregivers |
2 |
|
chinese health beliefs |
2 |
|
computational semantics |
2 |
|
confidence intervals |
2 |
|
connectome analysis |
2 |
|
copy number variation |
2 |
|
cost of illness |
2 |
|
cross-cultural comparison |
2 |
|
curriculum development |
2 |
|
data collection - methods - statistics and numerical data |
2 |
|
delirium - psychology |
2 |
|
dementia - psychology |
2 |
|
demography |
2 |
|
diffusion weighted mri |
2 |
|
family burdens |
2 |
|
first-episode psychotic disorder |
2 |
|
frontal lobe dysfunction |
2 |
|
functional laterality |
2 |
|
gender identity |
2 |
|
genome-wide association |
2 |
|
grey matter morphology |
2 |
|
grounded theory |
2 |
|
haplotype |
2 |
|
health knowledge, attitudes, practice |
2 |
|
high-risk |
2 |
|
ht1001 |
2 |
|
impulse control |
2 |
|
international |
2 |
|
linkage |
2 |
|
longitudinal study |
2 |
|
medical sciences - psychiatry and neurology |
2 |
|
mental disorders - diagnosis - epidemiology |
2 |
|
models, neurological |
2 |
|
network |
2 |
|
neural networks (computer) |
2 |
|
neurocognitive deficit |
2 |
|
neuropsychiatry |
2 |
|
neuropsychological deficits |
2 |
|
north american ginseng extract |
2 |
|
nutrition-based intervention |
2 |
|
other diagnostic or tool |
2 |
|
parkinson disease - psychology |
2 |
|
patient readmission |
2 |
|
peacefulness |
2 |
|
period of untreated psychosis |
2 |
|
phototherapy |
2 |
|
prediction error |
2 |
|
prefrontal cortex |
2 |
|
prevention strategies |
2 |
|
psychometrics |
2 |
|
public health |
2 |
|
public opinion |
2 |
|
rating scale |
2 |
|
rehabilitation |
2 |
|
rgs4 |
2 |
|
schizophrenia - diagnosis - genetics - rehabilitation |
2 |
|
schizophrenia - epidemiology |
2 |
|
schizophrenia - physiopathology |
2 |
|
screening |
2 |
|
seasonal affective disorder |
2 |
|
semantic networks |
2 |
|
sex distribution |
2 |
|
sick role |
2 |
|
spirituality |
2 |
|
subjective |
2 |
|
suicide - statistics and numerical data |
2 |
|
teaching methods |
2 |
|
verbal behavior |
2 |
|
volume |
2 |
|
volumetric |
2 |
|
weight dissatisfaction |
2 |
|
weight perception |
2 |
|
willpower |
2 |
|
acculturation |
1 |
|
acute mania |
1 |
|
african americans - psychology |
1 |
|
african continental ancestry group |
1 |
|
amnesia - physiopathology |
1 |
|
analysis of variance |
1 |
|
antipsychotic agents - administration & dosage |
1 |
|
antipsychotic agents - adverse effects - economics - therapeutic use |
1 |
|
antipsychotic agents - adverse effects - therapeutic use |
1 |
|
antipsychotic agents - pharmacology |
1 |
|
artificial neural network |
1 |
|
asian continental ancestry group - statistics & numerical data |
1 |
|
attention - drug effects |
1 |
|
attenuated psychotic symptoms |
1 |
|
attitude change |
1 |
|
backpropagation rule |
1 |
|
basal ganglia - physiopathology |
1 |
|
basal ganglia diseases - diagnosis - epidemiology - physiopathology |
1 |
|
basic symptoms |
1 |
|
bias (epidemiology) |
1 |
|
blink rate |
1 |
|
body weight - physiology |
1 |
|
brain - physiopathology |
1 |
|
brain damage, chronic - physiopathology |
1 |
|
brain injury |
1 |
|
cambridge neurological inventory |
1 |
|
catatonia - diagnosis - epidemiology - physiopathology |
1 |
|
category |
1 |
|
cerebral cortex - physiopathology |
1 |
|
chinese language |
1 |
|
chlorpromazine - administration & dosage - adverse effects |
1 |
|
cholesterol |
1 |
|
chronic disease |
1 |
|
cingulate |
1 |
|
clinical benefit |
1 |
|
clozapine - adverse effects - economics - therapeutic use |
1 |
|
clozapine - adverse effects - therapeutic use |
1 |
|
cognition disorders - diagnosis - etiology |
1 |
|
cognition disorders - etiology - psychology |
1 |
|
cognitive |
1 |
|
cognitive assessment |
1 |
|
cognitive behavioral therapy |
1 |
|
cognitive biases |
1 |
|
cognitive therapy |
1 |
|
cognitive-behavioural therapy |
1 |
|
color perception |
1 |
|
consumer survivor service user measures |
1 |
|
cooperation |
1 |
|
cross-sectional studies |
1 |
|
cross-validation |
1 |
|
data interpretation, statistical |
1 |
|
decision support techniques |
1 |
|
default mode network |
1 |
|
definitions |
1 |
|
delayed-action preparations |
1 |
|
delusions - chemically induced |
1 |
|
delusions - diagnosis - epidemiology - etiology - psychology |
1 |
|
depersonalization - chemically induced |
1 |
|
depressive disorder - drug therapy |
1 |
|
diagnosis, differential |
1 |
|
dipole |
1 |
|
discordant siblings |
1 |
|
disease progression |
1 |
|
dopamine system |
1 |
|
dose-response relationship, drug |
1 |
|
drug-induced liver injury - etiology |
1 |
|
dynamic causal modeling |
1 |
|
dyskinesias - diagnosis - epidemiology - physiopathology |
1 |
|
early intervention in psychosis |
1 |
|
eastern europe |
1 |
|
editorial |
1 |
|
effective connectivity |
1 |
|
endpoint determination |
1 |
|
england |
1 |
|
erectile dysfunction - chemically induced |
1 |
|
evidence-based medicine |
1 |
|
executive functions |
1 |
|
extrapyramidal signs |
1 |
|
eye movements |
1 |
|
fatty acids |
1 |
|
fmri |
1 |
|
frontal cortex |
1 |
|
frontal lobe - physiopathology |
1 |
|
functional connectivity |
1 |
|
game theory |
1 |
|
games, experimental |
1 |
|
group cognitive behavioural therapy |
1 |
|
group therapy |
1 |
|
health care surveys |
1 |
|
health planning |
1 |
|
hippocampus - physiopathology |
1 |
|
implementation |
1 |
|
informed consent |
1 |
|
injections, intramuscular |
1 |
|
intelligence tests |
1 |
|
language disorders - diagnosis - etiology |
1 |
|
language tests |
1 |
|
levodopa - administration & dosage - adverse effects |
1 |
|
lipid biology |
1 |
|
lipids |
1 |
|
lipids - blood |
1 |
|
lithium |
1 |
|
liver function tests |
1 |
|
longitudinal studies |
1 |
|
matched-pair analysis |
1 |
|
medical education |
1 |
|
memory disorders - etiology |
1 |
|
memory, short-term |
1 |
|
mental competency |
1 |
|
mental disorders - classification - diagnosis - psychology |
1 |
|
mental health recovery measures |
1 |
|
mental recall |
1 |
|
mental recall - physiology |
1 |
|
methodological study |
1 |
|
mismatch negativity (mmn) |
1 |
|
monotone counting |
1 |
|
motor coordination |
1 |
|
motor program |
1 |
|
motor sequencing |
1 |
|
motor skills disorders - etiology |
1 |
|
movement disorder |
1 |
|
multilayer perceptron |
1 |
|
neurocognitive dysfunction |
1 |
|
neurologic examination |
1 |
|
neurologic manifestations |
1 |
|
neurological manifestations |
1 |
|
neurological signs |
1 |
|
norms |
1 |
|
observer variation |
1 |
|
obsessive-compulsive disorder |
1 |
|
omega-3 |
1 |
|
omega-3 fatty acids |
1 |
|
omega-3 index |
1 |
|
outcome measures |
1 |
|
paranoia |
1 |
|
paranoid disorders - psychology |
1 |
|
parkinson disease - drug therapy - psychology |
1 |
|
patient admission |
1 |
|
patient compliance |
1 |
|
personality assessment |
1 |
|
phenotypes |
1 |
|
phosphatidylcholine |
1 |
|
phosphatidylethanolamine |
1 |
|
phosphatidylserine |
1 |
|
poly-unsaturated fatty acids |
1 |
|
prefrontal function |
1 |
|
premotor cortex |
1 |
|
priapism - chemically induced |
1 |
|
problem-solving |
1 |
|
prospective studies |
1 |
|
psychiatric service |
1 |
|
psychiatrists |
1 |
|
psychomotor performance - physiology |
1 |
|
psychotic disorders - diagnosis - psychology - rehabilitation |
1 |
|
quetiapine extended release |
1 |
|
rct |
1 |
|
reaction time |
1 |
|
reading |
1 |
|
reflex, abnormal |
1 |
|
resting-state |
1 |
|
risperidone - adverse effects - therapeutic use |
1 |
|
risperidone - therapeutic use |
1 |
|
roc curve |
1 |
|
rsvp |
1 |
|
schizophrenia - blood - drug therapy |
1 |
|
schizophrenia - complications - diagnosis - physiopathology |
1 |
|
schizophrenia - complications - epidemiology |
1 |
|
schizophrenia - complications - physiopathology |
1 |
|
schizophrenia - diagnosis - rehabilitation |
1 |
|
schizophrenia - drug therapy - economics |
1 |
|
schizophrenia - epidemiology - physiopathology |
1 |
|
schizophrenia - physiopathology - therapy |
1 |
|
schizophrenia - therapy |
1 |
|
schizophrenia/drug therapy |
1 |
|
schizophrenic language |
1 |
|
self mutilation - psychology |
1 |
|
semantic store |
1 |
|
semantics |
1 |
|
sensitivity and specificity |
1 |
|
sensorimotor cortex |
1 |
|
sma |
1 |
|
social adjustment |
1 |
|
social behaviour |
1 |
|
social environment |
1 |
|
soft neurological signs |
1 |
|
south east asia |
1 |
|
specificity |
1 |
|
spect |
1 |
|
sphingomyelin |
1 |
|
strategy |
1 |
|
stroop effect |
1 |
|
subjective distress |
1 |
|
supervisory attention |
1 |
|
supervisory attention system |
1 |
|
supervisory attentional system |
1 |
|
sustained attention |
1 |
|
symptom trajectories |
1 |
|
synapses - physiology |
1 |
|
task performance and analysis |
1 |
|
theory of mind |
1 |
|
transdiagnostic |
1 |
|
transition to psychosis |
1 |
|
treatment resistant |
1 |
|
triglycerides |
1 |
|
triglycerides - blood |
1 |
|
ultra high risk |
1 |
|
ultra-high risk for psychosis |
1 |
|
ultra-high-risk |
1 |
|
unaffected sibling |
1 |
|
urethra - injuries |
1 |
|
valproate |
1 |
|
verbal fluency |
1 |
|
verbal learning |
1 |
|
visual perception |
1 |
|
wechsler scales |
1 |
|
west indies - ethnology |
1 |
